From the Journals

Study: No increased mortality with ACA-prompted readmission declines

View on the News

Time to reexamine, reengineer HRRP?

The findings by Dharmarajan and colleagues are “certainly good news,” Karen E. Joynt Maddox, MD, wrote in an editorial.

The study provides support for strategies that hospitals are using to reduce readmissions, and also underscores the importance of evaluating unintended consequences of policy changes such as the Affordable Care Act’s Hospital Readmissions Reduction Program (HRRP), she said (JAMA. 2017 Jul 18;318[3]:243-4).

The study did not address the possibility that attention to reducing readmissions has taken priority over reducing mortality, which could have the unintended consequence of slowing improvements in mortality, she noted, suggesting that for this and other reasons it may be “time to reexamine and reengineer the HRRP to avoid unintended consequences and to ensure that its incentives are fully aligned with the ultimate goal of improving the health outcomes of patients.

“Only with full knowledge of the advantages and disadvantages of a particular policy decision can policy makers and advocates work to craft statutes and rules that maximize benefits while minimizing harms,” she wrote.

Dr. Joynt Maddox is with Brigham and Women’s Hospital, Boston. She is supported by a grant from the National Heart, Lung, and Blood Institute.


 

FROM JAMA

Concerns that efforts to reduce 30-day hospital readmission rates under the Affordable Care Act’s Hospital Readmission Reduction Program might lead to unintended increases in mortality rates appear to be unfounded, according to a review of more than 6.7 million hospitalizations for heart failure, acute myocardial infarction, or pneumonia between 2008 and 2014.

In fact, reductions in 30-day readmission rates among Medicare fee-for-service beneficiaries are weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge, according to Kumar Dharmarajan, MD, of Yale New Haven (Conn.) Health, and colleagues (JAMA 2017 Jul 18;318[3]:270-8. doi: 10.1001/jama.2017.8444).

Admitting & Outpatients sign Copyright Kimberly Pack/Thinkstock
During the study period, a total of 2.96 million hospitalizations for heart failure, 1.2 million for acute MI, and 2.5 million for pneumonia were identified at 5,106 (heart failure), 4,772 (MI), and 5,057 (pneumonia) short-term acute care hospitals, respectively. In January 2008, the mean hospital 30-day risk-adjusted readmission rates (RARRs) and risk-adjusted mortality rates (RAMRs) after discharge were 24.6% and 8.4% for heart failure, 19.3% and 7.6% for acute MI, and 18.3% and 8.5% for pneumonia, respectively, the investigators said.

From 2008 to 2014, the RARRs declined in aggregate across hospitals (–0.053% for heart failure, –0.044% for acute MI, and –0.033% for pneumonia).

“In contrast, monthly aggregate trends across hospitals in 30-day risk-adjusted mortality rates after discharge varied by admitting condition” the investigators said.

For heart failure, acute MI, and pneumonia, there was an increase of 0.008%, a decrease of 0.003%, and an increase of 0.001%, respectively, they said. However, paired monthly trends in 30-day RARRs and 30-day RAMRs after discharge “identified concomitant reduction in readmission and mortality rates within hospitals.”

Correlation coefficients of the paired monthly trends for heart failure, acute MI, and pneumonia in 2008-2014 were 0.066, 0.067, and 0.108, respectively.

“Paired trends in hospital 30-day risk-adjusted readmission rates and both 90-day risk-adjusted mortality rates after discharge and 90-day risk-adjusted mortality rates after the admission date also identified concomitant reductions in readmission and mortality rates within hospitals,” the authors wrote.

The findings “do not support increasing postdischarge mortality related to reducing hospital readmissions,” they concluded.

The authors work under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures. Dr. Dharmarajan reported serving as a consultant and scientific advisory board member for Clover Health at the time this research was performed. He is supported by grants from the National Institute on Aging and the American Federation for Aging Research, and the Yale Claude D. Pepper Older Americans Independence Center.

Recommended Reading

Pneumococcal conjugate vaccines modestly reduce complex acute otitis media
MDedge Family Medicine
Children with HIV benefit from double dose of PCV13 vaccine
MDedge Family Medicine
Vaccine reduced risk for flu visits by 42%
MDedge Family Medicine
New C. difficile drug shows promise
MDedge Family Medicine
Subsequent squamous cell carcinoma risk higher in HIV patients with low CD4 count
MDedge Family Medicine
Vancomycin research reveals reasons for readmissions and prolonged stays
MDedge Family Medicine
Asymptomatic maternal Zika infection doesn’t dampen birth defect risk
MDedge Family Medicine
Preventing Zika in pregnancy: What you need to know
MDedge Family Medicine
Antiviral shows early promise for treatment of Zika infection
MDedge Family Medicine
High-dose vitamin D fails against young children’s upper respiratory infections
MDedge Family Medicine

Related Articles